Rectal Cancer: Phase 3 Trial Comparing Surgical Approaches Completes Primary

A Phase 3 clinical trial comparing endoscopic transanal proctectomy with standard transabdominal laparoscopic proctectomy for rectal cancer reached its primary completion on 2025-09-01. The study enrolled 226 participants to evaluate the efficacy, morbidity, and functional outcomes of these two surgical approaches.

Background

Standard surgical treatment for mid and low rectal cancer involves total mesorectal excision (TME). Historically performed as open surgery, TME has been shown to improve local control and reduce urogenital morbidity. The adoption of a laparoscopic approach for TME, validated by several randomized controlled trials, offers patients benefits such as improved post-operative recovery and a lower risk of wound hernia, while maintaining comparable oncological results. However, the laparoscopic approach still carries a significant risk of conversion to an open procedure. Endoscopic transanal proctectomy represents an alternative technique, allowing for retrograde mesorectal excision and potentially completing the entire pelvic dissection endoscopically.

Trial design

This completed Phase 3 study, NCT02584985, enrolled 226 participants diagnosed with Rectal Cancer. The trial's objective was to evaluate and compare the efficacy, morbidity, and functional outcomes between two surgical interventions: endoscopic transanal proctectomy and standard transabdominal laparoscopic proctectomy. The study aimed to assess whether the newer endoscopic approach offers advantages over the established laparoscopic method for rectal cancer treatment.

What this means

The primary completion of this Phase 3 trial signifies a crucial step toward understanding the comparative benefits and risks of endoscopic transanal proctectomy versus standard laparoscopic proctectomy for rectal cancer. With 226 participants, the study is designed to provide robust data on surgical outcomes, potentially influencing future surgical standards and patient care for individuals with mid and low rectal cancer. Clinicians and patients await the full results, which could offer insights into recovery, complications, and long-term functional outcomes associated with each procedure.

Source

Information regarding the primary completion of this trial was sourced from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT02584985, titled "Evaluate Efficacy, Morbidity and Functional Outcome of Endoscopic TranAnal Proctectomy vs Standard Transabdominal Laparoscopic Proctectomy for Rectal Cancer," was posted on 2025-09-01 on clinicaltrials.gov.